Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. The MarketVue: Tardive Dyskinesia (TD) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market. According to experts interviewed, most patients with Tardive Dyskinesia (TD) are effectively managed using one of the two FDA-approved VMAT2 inhibitors, Austedo and Ingrezza. These medications are seen as comparable in terms of efficacy, side effect profiles, and now dosing convenience, with the introduction of Austedo extended-release tablets. As a result, the choice between the two often depends on physician preference, shaped by their prior experience with the drugs. Despite the success of these treatments, the report suggests that there is no significant unmet need for new TD treatments, reflected in the limited pipeline for TD therapies. However, the increasing us
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.MarketBeat
- Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]Yahoo! Finance
- Stocks making the biggest moves after hours: Adobe, RH, Oracle and more [CNBC]CNBC
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaPR Newswire
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferencePR Newswire
NBIX
Earnings
- 8/1/24 - Beat
NBIX
Sec Filings
- 9/13/24 - Form 144
- 8/28/24 - Form 8-K
- 8/16/24 - Form 4
- NBIX's page on the SEC website